Compare LPRO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPRO | CGEM |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 671.7M |
| IPO Year | N/A | 2021 |
| Metric | LPRO | CGEM |
|---|---|---|
| Price | $1.62 | $10.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $2.83 | ★ $28.00 |
| AVG Volume (30 Days) | 513.2K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,948,000.00 | N/A |
| Revenue This Year | $306.66 | N/A |
| Revenue Next Year | $7.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $5.68 |
| 52 Week High | $6.73 | $13.33 |
| Indicator | LPRO | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 48.91 |
| Support Level | $1.58 | $9.48 |
| Resistance Level | $1.87 | $13.10 |
| Average True Range (ATR) | 0.10 | 0.92 |
| MACD | -0.01 | -0.33 |
| Stochastic Oscillator | 14.52 | 17.40 |
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.